Key result
Non-Hodgkin lymphoma survivors show significantly lower heart rate variability within one year post-treatment.
Why the study?
Non-Hodgkin lymphoma is the most common blood cancer, and its usual treatments can cause heart failure.
Does non-Hodgkin lymphoma survivorship affect cardiac autonomic balance compared to healthy controls?
Observational (n=32)
No
Does non-Hodgkin lymphoma survivorship affect cardiac autonomic balance compared to healthy controls?
Non-Hodgkin lymphoma survivors exhibit reduced heart rate variability in the first year post-treatment, indicating autonomic imbalance that may be relevant to subsequent heart failure risk.
Answers are grounded in this paper and cite their sources.
May signal early autonomic dysfunction in non-Hodgkin lymphoma survivors; leaves open predictive value for heart failure and requires prospective validation.
Among the types of blood cancers, non-Hodgkin lymphoma is the most common. The usual treatments for this type of cancer can cause heart failure. A descriptive observational study was conducted that included 16 non-Hodgkin lymphoma survivors and 16 healthy controls matched by age and sex. Vagal tone was evaluated in the short term with a three-channel Holter device, and the time and frequency domains were analyzed following a previously accepted methodology to evaluate cardiac autonomic balance. The results of the analysis revealed that the standard deviation of the NN interval (F = 6.25, p = 0.021) and the square root of the mean of the sum of the differences between NN intervals (F = 9.74, p = 0.004) were significantly higher in healthy subjects than in lymphoma survivors. In the heart rate variability (HRV) index, there were no significant differences between the groups (F = 0.03, p = 0.85), nor in the parameters of the frequency domains LF (F = 1.94, p = 0.17), HF (F = 0.35, p = 0.55), and the ratio LF/HF (F = 3.07, p = 0.09). HRV values were lower in non-Hodgkin lymphoma survivors in the first year after treatment, resulting in autonomic imbalance compared to healthy paired subjects.
No takes yet. Share an insight, caveat, or question.
Vargas-Román et al. (2021) conducted an observational in Non-Hodgkin lymphoma (n=32). Non-Hodgkin lymphoma survival (6-12 months post-treatment) vs. Healthy age- and sex-matched controls was evaluated on Heart rate variability time domain parameters: RMSSD and SDNN (F = 9.74 (RMSSD); F = 6.25 (SDNN), p=0.004). Non-Hodgkin lymphoma survivors exhibited lower heart rate variability in RMSSD and SDNN compared to healthy controls in the first year post-treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: